Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunic, Inc. filings document SEC reporting for a Nasdaq-listed biotechnology company developing oral therapies for neurologic disease. Recent Form 8-K reports cover financial results and corporate updates, Nasdaq minimum bid price compliance, stockholder-approved charter amendments, and the reverse stock split affecting its common stock.
Governance disclosures include director and officer appointments, executive compensation arrangements, special-meeting voting results, and definitive proxy materials. The filings also describe registered common stock, capital-structure changes, financing and clinical-program updates, and formal governance and shareholder voting subjects tied to Immunic's late-stage development model.
Immunic, Inc. reported a first-quarter 2026 net loss of $32.6 million, wider than the $25.5 million loss a year earlier, as operating expenses rose to $33.2 million driven mainly by research and development spending of $25.6 million.
Financing activity significantly strengthened the balance sheet. A February 2026 private placement of pre-funded and common warrants generated gross proceeds of $200 million and net proceeds of $187.3 million, lifting cash and cash equivalents to $186.6 million as of March 31, 2026, compared with $15.5 million at year-end 2025. Management states these funds are expected to support operations for more than twelve months.
The company also completed a 1-for-10 reverse stock split effective April 27, 2026, regained compliance with Nasdaq’s minimum bid price requirement, and continued advancing its late-stage pipeline, including Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis and a Phase 2 program in progressive multiple sclerosis.
Immunic, Inc. Schedule 13G: A group led by Millennium-affiliated entities filed a joint Schedule 13G reporting shared beneficial positions in Immunic common stock. Integrated Core Strategies (US) LLC reported 743,281 shares (5.4%). Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each reported 793,621 shares (5.7%). The filing references a Joint Filing Agreement dated May 5, 2026 and notes shares are held by entities subject to voting and investment discretion by Millennium-affiliated managers.
Immunic, Inc. amends its shelf registration to reflect a 1-for-10 reverse stock split and to register for resale up to 45,815,180 shares of common stock by selling stockholders. The shares consist of up to 22,907,590 pre-funded warrant shares and 22,907,590 common warrant shares originally issued in a February 12, 2026 private placement.
The filing states the company will not receive proceeds from resale transactions, although it would receive proceeds if the warrants are exercised for cash; aggregate exercise proceeds are approximately $200.0M. The prospectus notes the Resale Shares equal ~336% of outstanding common stock (post-split basis) and discloses a Nasdaq closing price of $9.98 per share on April 27, 2026.
Immunic, Inc. granted Chief Medical Officer Michael A. Panzara a stock option covering 300,000 shares of common stock. The option has an exercise price of $8.80 per share and expires on April 24, 2036, representing a compensation-related award rather than an open-market trade.
According to the vesting terms, 50% of the underlying 300,000 shares will vest on April 24, 2027, and the remaining 50% will vest in 24 equal monthly installments, as long as he remains an employee of Immunic in good standing through each vesting date.
IMMUNIC, INC. filed an initial Form 3 for Chief Medical Officer Michael A. Panzara, establishing his status as a reporting person for the company’s securities. The filing does not list any buy, sell, or derivative transactions and serves as a baseline disclosure of insider reporting obligations.
Immunic, Inc. appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer effective April 24, 2026, succeeding co-founder Andreas Muehler, M.D., M.B.A., who resigned as CMO and will transition to a consulting role.
Dr. Panzara brings more than 25 years of neurology drug development experience from Neurvati, Wave Life Sciences, Sanofi Genzyme and Biogen, including work on several approved multiple sclerosis therapies. His employment terms include a $600,000 annual base salary, a target bonus of at least 50% of base salary, a $125,000 signing bonus and stock options to purchase 300,000 shares that vest over three years. Dr. Muehler will receive 12 months of base-salary severance from both Immunic and Immunic AG, full vesting of outstanding equity awards and a 10‑month consulting arrangement at $10,000 per month.
Immunic, Inc. is implementing a 1-for-10 reverse stock split of its common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026. Every 10 existing shares will be combined into 1 new share, reducing issued and outstanding shares from approximately 136 million to approximately 13.6 million, without changing the number of authorized shares or par value.
The split is intended primarily to allow Immunic to meet contractual obligations under a securities purchase agreement dated February 12, 2026. All stock options, warrants, restricted stock units and similar securities will be proportionally adjusted in share number and exercise price. No fractional shares will be issued; instead, the transfer agent will aggregate fractional interests, sell the resulting whole shares on the open market and distribute each stockholder’s cash share of the proceeds. Trading on the Nasdaq Capital Market under the symbol IMUX will continue, using a new CUSIP number 4525EP200 for the split-adjusted stock starting April 27, 2026.
Immunic, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III information on directors, executive officers, compensation and ownership that was previously omitted.
The filing also describes a 1-for-10 reverse stock split of common stock, approved by stockholders on April 14, 2026 and implemented by a charter amendment effective April 27, 2026. As of April 16, 2026, Immunic had 136,214,825 common shares outstanding and a non‑affiliate equity market value of $83.1 million based on the June 30, 2025 Nasdaq closing price.
The board has nine members, seven of whom are deemed independent under Nasdaq rules, and operates audit, compensation, and nominating and governance committees. The amendment outlines director retainers, stock option grants, 2025 executive pay, severance and change‑in‑control protections, equity plans and major institutional shareholders.
Immunic, Inc. ownership disclosure: Avidity Partners-related entities and Michael Gregory report shared beneficial ownership of 13,958,410 shares of Immunic common stock, representing 9.9% of the class.
The filing is a joint Schedule 13G listing the reporting persons, their Delaware/Cayman jurisdictions, shared voting and dispositive power over the same 13,958,410 shares, and a joint filing agreement. The signatures indicate Michael Gregory as managing member. The filing contains a disclaimer of beneficial ownership by each reporting person except for pecuniary interest.